Cholesterol-lowering therapy may retard the progression of diabetic nephropathy

Summary There is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury. We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus. Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin, an HMG CoA reductase inhibitor (n=16; mean dose 30.0±12.6 mg/day) or placebo (n=18) for 2 years. Renal function was assessed by serially measuring the serum creatinine, glomerular filtration rate (using Cr⁵¹-EDTA), and 24-h urinary protein excretion. Lovastatin treatment was associated with significant reductions in total cholesterol (p<0.001), LDL-cholesterol (p<0.001) and apo B (p<0.01), the reductions at 24 months being 26, 30 and 18%, respectively. Beneficial effects on serum triglyceride, HDL-cholesterol and apo A1 levels were also observed. Lp(a) showed no significant change in both groups. Glomerular filtration rate deteriorated significantly in the placebo group after 24 months (p<0.025) but showed no significant change in the lovastatin-treated patients. The increase in serum creatinine was statistically significant (p<0.02) in placebo-treated patients at 12 and 24 months, and in the lovastatin group after 24 months. Twenty-four hour urinary protein excretion increased in both groups (p<0.05). Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes. We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy.Abbreviations NIDDM Non-insulin-dependent diabetes mellitus - GFR glomerular filtration rate - Lp(a) lipoprotein(a) - apo apolipoprotein - LDL low-density lipoprotein - VLDL very low density lipoprotein - HDL high-density lipoprotein